TMCnet News
Paragonix Technologies, Inc., Announces Publication of "Innovative Cold Storage of Donor Organs Using the Paragonix Sherpa Pak™ Devices" in the Scientific Journal Heart, Lung and Vessels.Paragonix Technologies, Inc. today announced publication of "Innovate Cold Storage Of Donor Organs Using The Paragonix Sherpa Pak Devices"1 by investigators from the Transplantation Biology Research Center, Department of Surgery, Massachusetts General Hospital and Harvard Medical School (Boston) and the Department of Cardiac Surgery, Ludwig-Maximilians-University (Munich, Germany). Sebastian Michel, MD, first author of the study on faculty at the Department of Cardiac Surgery, Ludwig-Maximilians-University, commented, "We are delighted to present data regarding a new, innovative organ preservation technology. This study focused on testing the robustness of the single-use Paragonix Sherpa Pak™ organ transport device, which is designed to maintain constant organ preservation temperatures between 4°C to 8°C. In several evaluations, Sherpa Pak™ was challenged to extremely high and low external temperatures during organ storage. Our data demonstrated that internal organ preservation temperatures were maintained within the design range. We further concluded that the Paragonix Sherpa Pak™ device may decrease cold injury of donor organs undergoing transport and preservation by maintaining the temperature consistently between 4°C to 8°C, thereby potentially decreasing early primary graft failure after organ transplantation." Bill Edelman (News - Alert), CEO and Chairman, for Paragonix commented, "The Paragonix Sherpa Pak™ devices for kidney and heart preservation are an important step in improving donor organ transportation. We believe that improving the utilization of donated organs is critical to patients who are desperate for this precious commodity."
Previous Announcements Paragonix previously announced on December 2, 2014, clearance of two 510(k) Premarket Notifications by the US Food and Drug Administration, allowing the Paragonix Sherpa Pak Transport Systems to be combined and distributed with anyFDA-cleared, commercially-available preservation solution. Paragonix previously announced on Nov 17, 2014, Receipt of ISO 13485:2003 Certification for the Paragonix Sherpa Organ Storage and Transport Systems. Paragonix previously announced on Nov 3, 2014, filing of two 510(k) FDA Pre-Market Notifications to combine the Paragonix Sherpa Pak Cardiac and Kidney Transport Systems with any effective organ preservation solution currently marketed under 510(k) Pre-market Clearance. Paragonix previously announced on Oct 27, 2014, joining of David D'Alessandro, MD, as Medical Director for Paragonix.
About Ludwig-Maximilians-University (Munich, Germany)
About Massachusetts General Hospital
About the Paragonix Sherpa™ Portfolio of Organ Transport Technologies About Paragonix Technologies, Inc. Based in Braintree, Massachusetts, and founded in 2010, Paragonix Technologies, Inc., is a privately held medical device company innovating the Paragonix Sherpa™, a novel, single-use organ preservation device. Paragonix has exclusively licensed University of Texas Health Science Center San Antonio intellectual property from the Office of Technology Transfer and Commercialization. Paragonix has established a pipeline of donor organ transport devices that addresses the current donor organ shortage by maximizing donor organ utilization and improving donor organ quality throughout the entire United States.
1 Heart, Lung and Vessels; (in press) - http://www.heartlungandvessels.org View source version on businesswire.com: http://www.businesswire.com/news/home/20150723005093/en/ |